ClinicalTrials.gg
CompletedNCT06729970Updated Feb 24, 2026

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

A Phase 1 interventional study of Xanomeline/Trospium Chloride and Lithium in Healthy Volunteers, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
133
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effects of lithium, valproic acid, and lamotrigine on the single-dose pharmacokinetics (PK) of KarXT and the effect of KarXT on the single-dose PK of lithium, valproic acid, and lamotrigine in healthy participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • KarXT
  • Lithium
  • Valproic acid
  • Drug-Drug Interaction study
  • Healthy Volunteers
  • BMS-986510
  • Pharmacokinetics
  • Lamotrigine
03

In context

Lead sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female [individual not of (INOCBP)] participants as determined by no deviation from normal in medical history, physical examination, 12-lead , vital signs, and clinical laboratory determinations.
  • of 18.0 to 32.0 kg/m2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results. Note: Any grade of hepatic impairment ( Grade A or higher) is excluded.
  • Parts B and D only: History of pancreatitis.
  • Any significant acute or chronic medical illness, in the opinion of the investigator.
  • History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma or known history of prostate hypertrophy or nocturia.
  • Parts E \& F only: history of skin rash and mucus ulcerations of no obvious cause and Gilbert's syndrome
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Part A

    Drug: Xanomeline/Trospium Chloride · Drug: Lithium

  • Experimental
    Part B

    Drug: Xanomeline/Trospium Chloride · Drug: Valproic Acid

  • Experimental
    Part C

    Drug: Xanomeline/Trospium Chloride · Drug: Lithium

  • Experimental
    Part D

    Drug: Xanomeline/Trospium Chloride · Drug: Valproic Acid

  • Experimental
    Part E

    Drug: Xanomeline/Trospium Chloride · Drug: Lamotrigine

  • Experimental
    Part F

    Drug: Xanomeline/Trospium Chloride · Drug: Lamotrigine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to day 54

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to day 54

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to day 54

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 28 days post discontinuation of dosing

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 28 days post discontinuation of dosing

  3. Number of participants with physical examination abnormalities

    Time frame: Up to 2 days post discontinuation of dosing

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 2 days post discontinuation of dosing

  5. Number of participants with 12-lead electrocardiogram (ECG) abnormalities

    Time frame: Up to 2 days post discontinuation of dosing

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 2 days post discontinuation of dosing

  7. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 2 days post discontinuation of dosing

  8. Number of participants with AEs of Special Interest (AESIs)

    Time frame: Up to 28 days post discontinuation of dosing

07

Study locations

1 site
  • Local Institution - 0001
    Los Alamitos, California 90720-3115, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jan 2026, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 12, 2024
StartActual
Dec 26, 2024
Primary completionActual
Jan 23, 2026
CompletionActual
Jan 23, 2026
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06729970
Responsible party
Sponsor
First posted
Dec 12, 2024
Start date
Dec 26, 2024
Primary completion
Jan 23, 2026
Completion
Jan 23, 2026
Last update
Feb 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lithium · Valproic Acid · Lamotrigine

Start the discussion